On February 25, 2026, bioAffinity Technologies, Inc. announced a new study with Brooke Army Medical Center to validate the use of the CyPath® Lung diagnostic test for early lung cancer detection from sputum samples.
AI Assistant
BIOAFFINITY TECHNOLOGIES INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.